Abstract
We present a case of breast carcinoma, which was followed by acute leukemia within 1 month of diagnosis of the former. She had undergone a modified radical mastectomy for her breast cancer and had not received chemotherapy or radiotherapy. Acute leukemia as a result of chemotherapy for breast carcinoma is well known. However, patients developing synchronous breast carcinoma and acute leukemia, in the absence of any chemotherapy or radiotherapy, are rare.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pedersen-Bjergaard Jens (2002) Chemicals and leukemia. In: Henderson ES, Lister TA (eds) Leukemia, 7th edn. Philadelphia, Saunders, p 181
Pagano L, Pulsoni A, Mele L, et al. (2001) Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group. Ann Oncol 12:203–207
Ershler WB, Robins HI, Davis HL, et al. (1982) Emergence of acute non-lymphocytic leukemia in breast cancer patients. Am J Med Sci 284:23–31
Smadja N, Krulik M, Genot JY, et al. (1983) Hematologic and cytogenetic study of two cases of acute leukemia associated with breast cancer. Cancer Genet Cytogenet 9:185–196
Carey RW, Holland JF, Sheehe P, Graham S (1967) Association of cancer of the breast and acute myelocytic leukemia. Cancer 20:1080–1088
Antonella C, Carlo D, Giulio B (2002) Letter to the editor: synchronous tumors: a proposal for standardization. Tumori 88:433–434
Parikh B, Advani S (1996) Pattern of second primary neoplasms following breast cancer. J Surg Oncol 63:179–182
Collins FS, Trent JM (2001) Cancer genetics. In: Braunwald E, Fauci AS, Hauser SL, et al. (eds) Harrison’s principles of internal medicine, 15thedn. McGraw Hill, New York, p 504
Borresen-Dale AL (2003) TP53 and breast cancer. Hum Mutat 21:292–300
Peller S, Rotter V (2003) TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 21:277–284
Bryan L (2002) The t(8;21) fusion protein, AML1–ETO, specifically represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia. Published online: 24 June 2002, doi:10.1038/nm726. Nat Med 8:743–750
Haupt Y, Maya R, Kazaz A, et al. (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299
Liu Y, Colosimo AL, Yang XJ, et al. (2000) Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. Mol Cell Biol 20:5540–5553
Yasuyuki N, Tomoki N, Hitoshi K, et al. (2000) Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia: Eur J Haematol 65:23
Hartmann A, Blaszyk H, Hofstaedter F, et al. (1998) P53 gene mutations as an indicator of poor prognosis and poor response to adjuvant therapy in breast cancer patients: a prospective study. Cancer Detect Prev 22 [Suppl 1]
Rosner F, Carey RW, Zarrabi MH (1978) Breast cancer and acute leukemia: report of 24 cases and review of the literature. Am J Hematol 4:151–172
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mishra, P.P., Mahapatra, M., Choudhry, V.P. et al. Synchronous occurrence of breast carcinoma and acute myeloid leukemia: case report and review of the literature. Ann Hematol 83, 541–543 (2004). https://doi.org/10.1007/s00277-004-0852-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-004-0852-0